Effects of prostacyclin inhibition on splanchnic hyposensitivity to glypressin in a hemorrhage-transfused rat model of portal hypertension

Scandinavian Journal of Gastroenterology

Volumn 35, Issue 4, 2000, Pages 426-432

  Wang, Sun Sang ^a   Chu, C J ^a   Lee, F Y ^a   Wu, S L ^a   Lin, H C ^a   Chan, C C ^a   Chang, F Y ^a   Lee, S D ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Glypressin; Hemorrhage; Hyposensitivity; Indomethacin; Nitric oxide; Portal hypertension; Prostacyclin

Indexed keywords

INDOMETACIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROSTACYCLIN; TERLIPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; ENZYME INHIBITION; ESOPHAGUS VARICES BLEEDING; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PRIORITY JOURNAL; RAT; VEIN LIGATION;

EID: 0034124629     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655200750024010     Document Type: Article

References (49)

1. 1. Bosch J, Mastai R, Kravetz D, Bruix J, Rigau J, Rodés J. Measurement of azygos venous blood flow in the evaluation of portal hypertension in patient with cirrhosis. Clinical and hemodynamic correlations in 100 patients. J Hepatol 1985;1: 125-39.
2. 2. Conn HO. Vasopressin and nitroglycerin in the treatment of bleeding varices: the bottom line. Hepatology 1986;6:523-5.
3. 3. Kravetz D, Cummings SA, Groszmann RJ. Hyposensitivity to vasopressin in a hemorrhage-transfused rat model of portal hypertension. Gastroenterology 1987;93:170-5.
4. 4. Valla D, Girod C, Lee SS, Braillon A, Lebrec D. Lack of vasopressin action on splanchnic haemodynamics during bleeding: a study in conscious, portal hypertensive rats. Hepatology 1988;8:10-5.
5. 5. Tsai YT, Lee FY, Lin HC, Lee SD, Hsia HC, Lin WJ, et al. Hyposensitivity to vasopressin in patients with hepatitis B-related cirrhosis during acute variceal hemorrhage. Hepatology 1991;13:407-12.
6. 6. Valla D, Geoffroy P, Girod C, Lebrec D. Circulatory actions of vasopressin in anesthetized rats with portal hypertension subjected to hemorrhage. J Hepatol 1986;2:328-39.
7. 7. Paller MS, Linas SL. Role of angiogensin II, alpha-adrenergic system and arginine vasopressin on arterial pressure in the rat. Am J Physiol 1984;246:H25-30.
8. 8. Haddy FT, Scott JB, Molnar JI. Mechanism of volume replacement and vascular constriction following hemorrhage. Am J Physiol 1965;208:169-81.
9. 9. Chu CJ, Lee FY, Wang SS, Chang FY, Lin HC, Hou MC, et al. Aminoguanidine ameliorates splanchnic hyposensitivity to glypressin in a haemorrhage-transfused rat model of portal hypertension. Clin Sci 1998;95:629-36.
10. 10. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995;22:332-54.
11. 11. Griffiths MJD, Messent M, MacAllister RJ, Evans TW. Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol 1993;110:963-8.
12. 12. Misko TP, Moore WM, Kasten TP, Nickols GA, Corbett JA, Tilton RG, et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993;233:119-25.
13. 13. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983;244:G52-7.
14. 14. Schrier RW, Caramelo C. Hemodynamic and hormonal alternations in hepatic cirrhosis. In: Epstein M, editor. The kidney in liver disease. Baltimore: Williams & Wilkins, 1988. p. 265-85.
15. 15. Lee FY, Albillos A, Colombato LA, Groszmann RJ. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology 1992;16:1043-8.
16. 16. Sieber CC, Groszmann RJ. In vitro hyporeactivity to methoxamine in portal hypertensive rats: reversal by nitric oxide inhibition. Am J Physiol 1992;262:G996-1001.
17. 17. Pizcueta P, Piqué JM, Fernández M, Bosch J, Rodés J, Whittle BJ, et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992; 103:1909-15.
18. 18. Lee FY, Albillos A, Colombato LA. Chronic Nχ-nitro-L-arginine administration corrects peripheral vasodilation and systemic capillary hypotension, and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology 1993;17:84-90.
19. 19. Sitzmann JV, Li SS, Adkinson NF. Evidence for role of prostacyclin as a systemic hormone in portal hypertension. Surgery 1991;109:149-53.
20. 20. Sitzmann JV, Campbell K, Wu Y, St Clair C. Prostacyclin production in acute, chronic and long-term experimental portal hypertension. Surgery 1994;115:290-4.
21. 21. Guarner C, Soriano G, Such J, Teixidó M, Ramis I, Bulbena O, et al. Systemic prostacyclin in cirrhotic patients. Relationship with portal hypertension and changes after intestinal decontamination. Gastroenterology 1992;102:303-9.
22. 2 and glucagon levels in humans. Ann Surg 1993;217:248-52.
23. 23. Sitzmann JV, Bulkley GB, Mitchell MC, Campbell K. Role of prostacyclin in the splanchnic hyperemia contributing to portal hypertension. Ann Surg 1989;209:322-7.
24. 24. Piqué JM, Leung FW, Kitahora T, Sarfeh J, Tarnawaski A, Guth PH. Gastric mucosal blood flow and acid secretion in portal hypertensive rats. Gastroenterology 1988;95:727-33.
25. 25. Bruix J, Bosch J, Kravetz D, Mastai R, Rodéz J. Effects of prostacyclin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985;88: 430-5.
26. 26. Sitzmann JV, Li SS, Lin PW. Prostacyclin mediates splanchnic vascular response to norepinephrine in portal hypertension. J Surg Res 1989;47:208-11.
27. 27. Wu Y, Li SS, Campbell KA, Sitzmann JV. Modulation of splanchnic vascular sensitivity to angiotensin II. Surgery 1991; 110:162-8.
28. 28. Chojkier M, Groszmann RJ. Measurement of the portal-systemic shunting in the rat by using γ-labeled microspheres. Am J Physiol 1981;240:G371-5.
29. 29. Whittle BJR, Vane JR. Prostanoids as regulators of gastrointestinal function. In: Johnson LR, editor. Physiology of the gastrointentinal tract. Vol 1. New York: Raven; 1989. p. 143-80.
30. 30. Fernández M, García-Pagán JC, Casadevall M, Mourelle MI, Piqué JM, Bosch J, et al. Acute and chronic cyclooxygenase blockade in portal-hypertensive rats: influence on nitric oxide biosynthesis. Gastroenterology 1996;110:1529-35.
31. 31. Krazier W, Moritz E, Schenk WG. Studies in experimental canine cirrhosis. Ann Surg 1973;177:503-6.
32. 1. Eur J Pharmacol 1982;77:147-51.
33. 33. Hamilton G, Phing RCF, Hutton RA, Dandona P, Hobbs KEF. The relationship between prostacyclin activity and pressure in the portal vein. Hepatology 1982;2:236-42.
34. 34. Guarner G, Guarner C, Prieto J, Colina I, Quiroga J, Casas J, et al. Increased synthesis of systemic prostacyclin in cirrhotic patients. Gastroenterology 1986;90:687-94.
35. 35. Reed MK, Taylor B, Myers SI. The effect of hypoxia on rat splanchnic prostanoid output. Prostaglandins 1989;38:599-608.
36. 2 from the splanchnic bed. J Trauma 1990;30:993-9.
37. 37. Dusting GJ, Moncada S, Vane JR. Vascular actions of arachidonic acid and metabolites in perfused mesenteric and femoral beds of the dog. Eur J Pharmacol 1978;49:65-72.
38. 38. Reed MK, Taylor BJ, Smith G, Phan T, Myers SI. Splanchnic prostanoid production: effect of hemorrhagic shock. J Surg Res 1990;48:579-83.
39. 39. Myers S, Bartula L. Long-term hyperalimentation following hemorrhage /reperfusion injury induces intestinal prostanoids synthesis. Circ Shock 1993;40:151-6.
40. 2 release following acute hemorrhage is due to new protein synthesis. Prostaglandins Leukot Essent Fatty Acids 1993;48:207-10.
41. 41. Wu Y, Burns C, Campbell KA, Sitzmann JV. Systemic and portal prostacyclin and thromboxane response to hemorrhage in portal hypertension. Shock 1994;2:68-71.
42. 42. Siegel JH, Greenspan M, Cohn JD, DelGuercio LRM. The prognostic implications of altered physiology in operations for portal hypertension. Surg Gyn Obstet 1968;1:249-62.
43. 43. Garrison RN, Cryer HM, Howard DA, Polk HC Jr. Clarification of risk factors for adominal operations in patients with hepatic cirrhosis. Ann Surg 1984;199:648-55.
44. 44. Wu Y, Burns RC, Sitzmann JV. Effects of nitric oxide and cyclooxygenase inhibition of splanchnic hemodynamics in portal hypertension. Hepatology 1993;18:1416-21.
45. 45. Blanchart A, Hernando N, Fernández-Munoz D, Hernando L, Lopez-Novoa JM. Lack of effect of indomethacin on systemic and splanchnic hemodynamics in portal hypertensive rats. Clin Sci 1985;68:605-7.
46. 46. Laycock JF, Penn W, Shirley DG, Walter SJ. The role of vasopressin in blood pressure regulation immediately following acute hemorrhage in the rat. J Physiol 1979;296:267-75.
47. 47. Wang BC, Sundet WD, Hakumaki MOK, Goetz KL. Vasopressin and renin response hemorrhage in conscious, cardiac denervated dogs. Am J Physiol 1983;245:H399-H405.
48. 48. Feuerstein G, Molineaux CJ, Rosenberger JG, Zerbe RL, Cox BM, Faden AI. Hemorrhagic shock and the central vasopressin and opoid peptide system of rats. Am J Physiol 1985;249:E244-50.
49. 49. Chan CC, Lee FY, Wang SS, Chang FY, Lin HC, Chu CJ, et al. Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats: role of nitric oxide and prostaglandin. Hepatology 1999;30:630-5.